Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.
Helene Häberle,Harry Magunia,Peter Lang,Henning Gloeckner,Andreas Körner,Michael Koeppen,Tamam Backchoul,Nisar P. Malek,Rupert Handgretinger,Peter Rosenberger,Valbona Mirakaj +10 more
Reads0
Chats0
TLDR
The COVID-19 pandemic reached Germany in spring 2020 and no proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID19-induced ARDS as mentioned in this paper.Abstract:
Background:The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether th...read more
Citations
More filters
Journal ArticleDOI
Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm
Ali A. Rabaan,Shamsah H. Al-Ahmed,Javed Muhammad,Amjad Khan,Anupam A Sule,Raghavendra Tirupathi,Abbas Al Mutair,Saad Alhumaid,Awad Al-Omari,Manish Dhawan,Ruchi Tiwari,Khan Sharun,Ranjan K. Mohapatra,Saikat Mitra,Muhammad Bilal,Salem A. Alyami,Talha Bin Emran,Mohammad Ali Moni,Kuldeep Dhama +18 more
Journal ArticleDOI
Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses
Ali A. Rabaan,Shamsah H. Al-Ahmed,Mohammed A. Garout,Ayman M. Al-Qaaneh,Anupam A Sule,Raghavendra Tirupathi,Abbas Al Mutair,Saad Alhumaid,Abdulkarim Hasan,Manish Dhawan,Ruchi Tiwari,Khan Sharun,Ranjan K. Mohapatra,Saikat Mitra,Talha Bin Emran,Muhammad Bilal,Rajendra Singh,Salem A. Alyami,Mohammad Ali Moni,Kuldeep Dhama +19 more
TL;DR: In this article, a review explains the interrelationships of hyper-inflammatory response or cytokine storm with organ damage and the disease severity and the authors have thrown light on the diverse mechanisms and risk factors that influence pathogenesis and the molecular pathways that lead to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and multiple organ damage.
Journal ArticleDOI
Mesenchymal stem cell therapy for severe COVID-19.
Journal ArticleDOI
Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial
Wei-Fen Xie,Fu-Sheng Wang +1 more
TL;DR: In this article , the authors evaluated the 1-year outcomes in patients with severe COVID-19, who were recruited in their previous UC-MSC clinical trial, and the results showed that the long-term consequences of human umbilical cord-derived mesenchymal stem cell treatment for COVID19 patients are yet to be reported.
Journal ArticleDOI
Mesenchymal stem cell treatment for COVID-19
TL;DR: Wang et al. as mentioned in this paper summarized the major pathological characteristics of COVID-19 and provided scientific and rational evidence for the safety and possible effectiveness of mesenchymal stem cells (MSCs) in COVID -19 treatment.
References
More filters
Journal ArticleDOI
Transplantation of ACE2 - Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.
Zikuan Leng,Rongjia Zhu,Wei Hou,Yingmei Feng,Yanlei Yang,Qin Han,Guangliang Shan,Fanyan Meng,Dongshu Du,Shihua Wang,Junfen Fan,Wenjing Wang,Luchan Deng,Hongbo Shi,Hongjun Li,Zhongjie Hu,Fengchun Zhang,Jinming Gao,Hongjian Liu,Xiaoxia Li,Yangyang Zhao,Kan Yin,Xijing He,Zhengchao Gao,Yibin Wang,Bo Yang,Ronghua Jin,Ilia Stambler,Lee Wei Lim,Huanxing Su,Alexey Moskalev,Antonio Cano,Sasanka Chakrabarti,Kyung-Jin Min,Georgina M. Ellison-Hughes,Calogero Caruso,Kunlin Jin,Robert Chunhua Zhao +37 more
TL;DR: The intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.
Journal ArticleDOI
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial
Jennifer G. Wilson,Kathleen D. Liu,Hanjing Zhuo,Lizette Caballero,Melanie McMillan,Xiaohui Fang,Katherine Cosgrove,Rosemary Vojnik,Carolyn S. Calfee,Jae-Woo Lee,Angela J. Rogers,Joseph E. Levitt,Jeanine P. Wiener-Kronish,Ednan K. Bajwa,Andrew D. Leavitt,David H. McKenna,B. Taylor Thompson,Michael A. Matthay +17 more
TL;DR: A single intravenous infusion of allogeneic, bone marrow-derived human MSCs was well tolerated in nine patients with moderate-to-severe ARDS, and this phase 1 trial has proceeded to phase 2 testing of M SCs for moderate to severe ARDS with a primary focus on safety and secondary outcomes including respiratory, systemic, and biological endpoints.
Journal ArticleDOI
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Michael A. Matthay,Carolyn S. Calfee,Hanjing Zhuo,B. Taylor Thompson,Jennifer G. Wilson,Joseph E. Levitt,Angela J. Rogers,Jeffrey E. Gotts,Jeanine P. Wiener-Kronish,Ednan K. Bajwa,Michael P. Donahoe,Bryan J. McVerry,Luis A. Ortiz,Matthew C. Exline,John W. Christman,Jason Abbott,Kevin L. Delucchi,Lizette Caballero,Melanie McMillan,David H. McKenna,Kathleen D. Liu +20 more
TL;DR: One dose of intravenous MSCs was safe in patients with moderate to severe ARDS, and the viability of M SCs must be improved.
Journal ArticleDOI
Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis
TL;DR: Way in which the paracrine effects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis are outlined and ongoing challenges in MSC research are summarised.
Journal ArticleDOI
Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation.
Ingo Müller,Sandra Kordowich,Christina Holzwarth,Gesa Isensee,Peter Lang,Felix Neunhoeffer,Massimo Dominici,Johann Greil,Rupert Handgretinger +8 more
TL;DR: Transfusion of MSC was safe and encouraging improvements in some patients were observed, and the first series of 11 transfusions of expanded MSC in pediatric patients with immunological complications after allogeneic transplantation are reported.
Related Papers (5)
Transplantation of ACE2 - Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.
Zikuan Leng,Rongjia Zhu,Wei Hou,Yingmei Feng,Yanlei Yang,Qin Han,Guangliang Shan,Fanyan Meng,Dongshu Du,Shihua Wang,Junfen Fan,Wenjing Wang,Luchan Deng,Hongbo Shi,Hongjun Li,Zhongjie Hu,Fengchun Zhang,Jinming Gao,Hongjian Liu,Xiaoxia Li,Yangyang Zhao,Kan Yin,Xijing He,Zhengchao Gao,Yibin Wang,Bo Yang,Ronghua Jin,Ilia Stambler,Lee Wei Lim,Huanxing Su,Alexey Moskalev,Antonio Cano,Sasanka Chakrabarti,Kyung-Jin Min,Georgina M. Ellison-Hughes,Calogero Caruso,Kunlin Jin,Robert Chunhua Zhao +37 more
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Giacomo Lanzoni,E. Linetsky,Diego Correa,Shari Messinger Cayetano,Roger A. Alvarez,Dimitrios Kouroupis,Ana M. Alvarez Gil,Raffaella Poggioli,Phillip Ruiz,Antonio Marttos,Khemraj Hirani,Crystal A. Bell,Halina Kusack,Lisa E. Rafkin,David A. Baidal,Andrew Pastewski,Kunal Gawri,Clarissa Leñero,Alejandro Mantero,Sarah W. Metalonis,Xiaojing Wang,Luis Roque,Burlett Masters,Norma S. Kenyon,Enrique Ginzburg,Xiumin Xu,Jianming Tan,Arnold I. Caplan,Marilyn K. Glassberg,Rodolfo Alejandro,Camillo Ricordi +30 more